Intracellular actions of steroid hormones and their therapeutic value, including the potential of radiohalosteroids against ovarian cancer
| Autor: | John A. Holt, Stig Kullander, A. Scharl, Matthias W. Beckmann |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Receptors
Steroid medicine.medical_specialty medicine.drug_class medicine.medical_treatment Estrogen receptor Biology Iodine Radioisotopes Radioligand Assay Heat shock protein Internal medicine medicine Radioligand Animals Humans Tissue Distribution Gonadal Steroid Hormones Receptor Ovarian Neoplasms Estradiol Radiotherapy Obstetrics and Gynecology General Medicine medicine.disease Steroid hormone Endocrinology Estrogen Cancer research Female Ovarian cancer Hormone |
| Zdroj: | Acta Obstetricia et Gynecologica Scandinavica. 71:39-54 |
| ISSN: | 0001-6349 |
| DOI: | 10.1111/j.1600-0412.1992.tb00006.x |
| Popis: | The biological activities of steroid hormones are effected via intracellular receptors. The receptors are part of a ligand-activated family of transcription regulator proteins that are critical for steroid-regulated cell differentiation. With recombinant cDNA technology, yeast and cultured animal cells can be made to express mammalian cDNA steroid receptors from cDNA clones that contain deletions and substitutions. Among the leading problems addressed in these models is the characterization of sequences that promote association or interaction with other transcription regulating molecules, including oncogene products. Recently it has been found that heat shock proteins may serve not only to stabilize the receptor proteins but also to precondition the activation imparted by ligand binding. Aberrant receptor proteins can be found in ovarian cancer. Whether aberrant receptor proteins are associated with transformation in general or with a variable clinical response to steroidal or anti-steroidal therapy is not known. Even after chemotherapy, steroid receptors are expressed in the metastases of ovarian cancers seen clinically, and they may have potential uses for localization and treatment of receptor-rich cancers. Radioligand pharmaceuticals appropriate for imaging or for site-directed radiocytotoxicity can be sequestered to the nuclei of receptor-rich cancers. Initial clinical imaging and therapy trials with such pharmaceuticals have been approved and begun. In the use of halogenated estrogen radiopharmaceuticals, liver metabolism and enterohepatic recirculation are important considerations. Ascites prolongs retention of a radiohalogenated estrogen in the abdominal cavity. Distant metastases have been localized with [123I]-estrogen in breast cancer patients in pre-operative procedures. Receptor-mediated cytotoxicity occurs when estrogen receptor radioligand pharmaceuticals that are Auger electron emitters are used in vitro. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|